Today's Date: February 8, 2023
MellingMedical Enhances Medical/Surgical Line with ATMOS Products   •   Sappi delivers solid performance for first financial quarter 2023   •   KISS Colors & Care is Excited to Announce Rap Sensation JT from CITY GIRLS as their NEW BRAND PARTNER and the introduction o   •   ThoroughCare, Honor My Decisions join forces to provide Advance Care Planning services   •   CCRM Fertility Announces Two New Office Locations in Washington, D.C. and Rockville, MD   •   Beyond Spots & Dots Recognized as Champion of Race and Culture Equality   •   Chrissy Teigen Partners with Cord Blood Registry®   •   Research Funding Available for Preeclampsia and Related Pregnancy Disorders   •   The Foundation for Black Communities to be awarded stewardship of $200 million Black-Led Philanthropic Endowment Fund by federal   •   KLAS Research ranks Wolters Kluwer’s Sentri7 #1 for Infection Control & Monitoring for second year   •   Work-Life Imbalance Cited as Top Stressor for Working Women Today, 24 Seven Report Finds   •   Large Real-World, Multi-Center Study Demonstrates Viz.ai Platform Saves Critical Minutes in Stroke Care   •   KLAS ranks Wolters Kluwer’s Emmi #1 for Patient Engagement: Patient-Driven Care Management   •   Ten UBS advisors in South Texas named to the Forbes Top Women Wealth Advisors list   •   Digital Banking User Growth Continued at Strong Pace in 2022   •   Gold Rabbit Sports Announces Strategic Partnership With Bio-Tech Start-Up Prothegen To Accelerate The Development Of Revolutiona   •   Children's Cancer Center Announces Vantagepoint A.I. As February Partner Of The Month   •   Kessler Foundation grants nearly $1 million to expand employment opportunities for people with disabilities striving to work in   •   reVolver Podcasts Launches New Shows on Amp, the Live Radio App from Amazon   •   INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Plug Power Inc. and Encourages Investors
Bookmark and Share

Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia

CAMBRIDGE, Mass. , December 05 /Businesswire/ - Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET.

The event will feature presentations by Syros management, who will review the initial SELECT-AML-1 data and plans for the randomized portion of the Phase 2 trial, as well as Daniel Pollyea, M.D., M.S., Associate Professor of Medicine, Clinical Director of Leukemia Services, University of Colorado School of Medicine, who will provide his perspective on the evolving treatment landscape.

Participants can register for the event here. In addition, a live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

Initial data from the SELECT-AML-1 trial will also be presented on Saturday, December 10, 2022 in a poster session at the 64th American Society of Hematology (ASH) Annual Meeting.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARĪ± agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.


STORY TAGS: Massachusetts, Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, United States, North America, Webcast, Product/Service, Event,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News